Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma

Cancer Immunology Research

Volumn 4, Issue 3, 2016, Pages 175-178

  Khoja, Leila ^a   Maurice, Catherine ^a   Chappell, Maryanne ^a   Macmillan, Leslie ^a   Al Habeeb, Ayman S ^a   Al Faraidy, Nada ^a   Butler, Marcus O ^a   Rogalla, Patrik ^a   Mason, Warren ^a   Joshua, Anthony M ^a   Hogg, David ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; MEPREDNISONE; PEMBROLIZUMAB; PREDNISONE; STEROID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE BRAIN DISEASE; ACUTE CONFUSION; ADULT; ARTICLE; BRAIN INFARCTION; BRAIN TOXICITY; BRAIN VASCULITIS; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION; CLEAR CELL SARCOMA; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONFABULATION; CONFUSION; DRUG DOSE INCREASE; DRUG MEGADOSE; EOSINOPHILIC FASCIITIS; FECES INCONTINENCE; FEMALE; HEADACHE; HUMAN; LUNG BIOPSY; LUNG SURGERY; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE PULMONARY NODULES; MUSCLE BIOPSY; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE; WEAKNESS; BRAIN DISEASES; CHEMICALLY INDUCED; EOSINOPHILIA; FASCIITIS; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN DISEASES; EOSINOPHILIA; FASCIITIS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84962019367     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0186     Document Type: Article

References (15)

1. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-95.
2. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Antiprogrammed-death-receptor-1 treatmentwith pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
4. Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF, et al. LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 2014;25 (suppl 4).
5. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.
6. Weber JS, Antonia SJ, Topalian SL, Schadendorf D, Larkin JMG, Sznol M, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. ASCO Meeting Abstracts 2015;33(15-suppl):9018.
7. Long H, Zhang G, Wang L, Lu Q. Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol 2015 Apr. 16. [Epub ahead of print].
8. Song YW, Kim HA, Song KY. Eosinophilic fasciitis with occlusive vasculitis and gangrene of the finger. J Rheumatol 1995;22:356-9.
9. Magaro M, Altomonte L, Zoli A, Mirone L, Massi G, Federico F. Eosinophilic fasciitis associated with inflammatory neutrophilic vasculitis. Br J Rheumatol 1990;29:145-6.
10. Cecchi PC, Caramaschi P, Pinna G, Schwarz A, Bricolo A. Haemorrhagic stroke and vasculitic-like cerebral angiography in a patient with eosinophilic fasciitis. Case report. J Neurosurg Sci 2006;50:119-22.
11. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
12. Lyle MK, Lee JH, Menzies AM, Chan MM, Clements A, Carlino MS, et al. Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM). ASCO Meeting Abstracts 2014;32(15-suppl):9077.
13. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO MeetingAbstracts 2014;32(15-suppl):LBA9000.
14. Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Antiprogrammed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 2015;64:765-7.
15. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.